We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 123

Pfizer v Ranbaxy; 55.2 proceeding; October 5, 2007 - atorvastatin

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • October 25 2007

The trial judge granted prohibition in respect of one patent claiming a novel crystalline form of atorvastatin (the "crystalline form patent") and denied prohibition in respect of another patent claiming a novel process for making atorvastatin (the "process patent"

Pfizer v. Apotex, PMNOC Regulations decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

Apotex alleged in its NOA that Pfizer's patent was invalid for double patenting, anticipation, obviousness, lack of utility and over-breadth

Solvay v Apotex; 55.2 proceeding; March 6, 2008; pantoprazole, application for prohibition dismissed

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 21 2008

The Court dismissed the application on the basis that Altana had not proven that the allegation of non-infringement was not justified

Astrazeneca v. Apotex, interlocutory motion to strike affidavit in PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

This was an appeal to the Federal Court of Appeal (FCA) of the decision of Justice Hughes refusing to strike an affidavit from the record

Sanofi-Aventis v. Laboratoire Riva; interlocutory motion on 55.2 proceeding; December 14, 2007 - Ramipril

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 17 2008

After cross-examinations had taken place, and approximately one week before the application record of Sanofi-Aventis was due, Riva brought a motion for leave to file further evidence

AstraZeneca v Novopharm, motion to adduce video-recordings of cross-examinations of expert witnesses in a PMNOC Regulations case

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • May 21 2010

AstraZeneca brought a motion seeking an order that video-recordings of cross-examinations of expert witnesses in the proceedings be filed as part of the Application Record and available at the hearing

Canada (Attorney General) v. Celgene Corporation, appeal of a PMPRB decision

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 20 2010

The Court of Appeal overturned the decision of the Trial Judge and restored the decision of the PMPRB providing jurisdiction to the PMPRB over medicines imported under the Special Access Program

Lundbeck v. Cobalt, Genpharm and Apotex

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 7 2009

The Court granted prohibition in respect of each of the proceedings against each defendant

Recent cases

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • August 21 2009

The Court granted an order of prohibition to Purdue in the face of Pharmascience’s allegations that the patent was invalid

PMPRB issues discussion paper on options to address the Federal Court decision in LEO Pharma

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 6 2008

The Patented Medicine Prices Review Board (PMPRB) has issued a discussion paper outlining a series of options to address the implications of the Federal Court of Canada decision in the LEO Pharma case